Temodal (temozolomide) is a medication that is commonly used to help with the management of certain aggressive brain tumours, which are conditions characterized by periods of heightened symptoms related to central nervous system functional stress. Its therapeutic uses center on malignant glioma, covering specific indications such as newly diagnosed glioblastoma multiforme and recurrent malignant glioma, including anaplastic astrocytoma in adults and children over three years old. The therapy is considered relevant for easing symptoms associated with acute or episodic changes in patients who have progressed following prior standard treatment. In these clinical domains, Temodal contributes to improved comfort during periods of heightened symptoms.

“The therapy may assist with maintaining stability when symptoms become more noticeable.”

This supportive treatment may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relevant for easing symptoms of increased neurological or muscular activity

Regulatory References

1. European Medicines Agency overview

Eligibility for Temodal (temozolomide)

The use of temozolomide is strictly defined by regulatory documents, which establish specific eligibility and non-eligibility criteria based on patient characteristics and clinical status.

Populations Allowed and Contraindicated

The medicine is generally approved for adult patients and pediatric patients aged 3 years and older who meet specific diagnostic criteria. However, temozolomide is contraindicated (must not be used) in patients with a history of hypersensitivity to the active ingredient, temozolomide, or to dacarbazine (DTIC). It is also contraindicated for patients presenting with severe myelosuppression (critically low blood cell counts).

Conditional Use and Restrictions

Treatment initiation is conditional on the patient's baseline hematological status, requiring an Absolute Neutrophil Count (1.5 imes 10^9/L) and a platelet count (100 imes 10^9/L). Caution should be exercised when administering to patients with severe hepatic or severe renal impairment, as data are limited in these populations. Use in children under 3 years is not established. The medicine is not recommended during breastfeeding, and patients with reproductive potential must use effective contraception due to the risk of fetal harm.

Interactions with other medicines and products for Temozolomide are formally documented by regulatory authorities, establishing specific constraints for its use.

Contraindicated Combination

Temozolomide is officially contraindicated in patients with a known hypersensitivity to Dacarbazine. This strict prohibition is based on the shared metabolic pathway that leads both compounds to the same active substance.

Drug-Drug Interactions (Pharmacokinetic)

The co-administration of valproic acid is documented to cause a reduction in the oral clearance of temozolomide by approximately five percent. Conversely, population pharmacokinetic studies have confirmed that several commonly coadministered medicines, including dexamethasone, ranitidine, phenytoin, and ondansetron, do not cause a clinically significant effect on the oral clearance of temozolomide.

Drug-Food Interaction and Timing

Food intake significantly affects the absorption of oral temozolomide, officially documented as reducing the drug's maximum concentration ( C max) by 32 percent and the overall exposure ( AUC) by nine percent. This pharmacokinetic interaction requires a specific timing rule: capsules must be administered in the fasting state (EU guidance) or administered consistently with respect to food (US guidance).

Population-Specific Caution

Official prescribing information requires caution when Temozolomide is administered to patients with severe hepatic impairment or severe renal impairment, as comprehensive pharmacokinetic interaction data for these specific populations are not fully available.

Spontaneous Chemical Activation and DNA Methylation

Temozolomide functions as a pro-drug, requiring spontaneous, non-enzymatic hydrolysis at physiological pH to initiate its mechanism of action. It converts into the highly reactive metabolite, MTIC, which then acts as an alkylating agent. This metabolite covalently modifies the cell's DNA, primarily by adding a methyl group to the O^6 position of the Guanine base. This molecular change establishes the critical lesion that activates the subsequent cellular mechanism.

---

The Futile Repair Cycle and Cytotoxicity

The cell’s internal DNA Mismatch Repair (MMR) pathway recognizes the methylated Guanine as damage but attempts to repair it unsuccessfully. This leads to a persistent sequence of repair initiation and failure, known as a futile repair cycle, which results in lethal DNA strand breaks. The subsequent accumulation of irreparable damage activates the apoptosis cascade, resulting in the inhibition of cellular replication and the induction of programmed cell death.

---

Constraints Imposed by the MGMT Enzyme

The entire cytotoxic mechanism is constrained by the presence of the cellular enzyme MGMT (O^6-methylguanine-DNA methyltransferase). High levels of MGMT expression directly reverse the initial molecular modification by removing the methyl group from the O^6-G lesion. This reversal prevents the formation of the critical DNA damage, thereby avoiding the activation of the lethal MMR-mediated cascade.

Temozolomide is administered either orally as hard capsules or via intravenous (IV) infusion, depending on the prescribed clinical context. The entire course of therapy is structured around a precise 28-day cyclic schedule.

Dosing and Schedule

The required dose is not fixed, but is calculated based on the patient's Body Surface Area (BSA) and expressed in milligrams per square meter (mg/m^2). For newly diagnosed glioblastoma, the concomitant phase involves a 75 mg/m^2 dose taken once daily for up to 49 consecutive days alongside radiotherapy. This is followed by a maintenance phase consisting of up to six cycles, where the dose typically ranges from 150 mg/m^2 to 200 mg/m^2. In the maintenance regimen, the dose is taken once daily for five consecutive days, followed by a 23-day break.

Administration Conditions and Timing

Administration requires adherence to specific timing and preparation rules. The oral capsules must be swallowed whole with water and are explicitly instructed not to be crushed, chewed, or opened. Intake is required to be in the fasting state, generally one hour before or two hours after a meal. For the IV route, the powder must be reconstituted and diluted prior to infusion, and the final solution must be delivered over a standard 90-minute period. A new cycle is initiated only after the preceding 23-day break and after predefined laboratory criteria for blood count recovery are met. If a dose is missed or if the patient vomits after taking it, it is instructed not to take a replacement dose; instead, the patient resumes the schedule with the next planned dose.

Research Evidence / Overview of Studies for Темодал

---

Evidence for Newly Diagnosed Glioblastoma Multiforme

Research examining the use of Temozolomide for newly diagnosed glioblastoma multiforme (GBM) is primarily based on large-scale, randomized controlled trials (RCTs). These pivotal studies examined a comparison between patients receiving radiotherapy alone and those receiving Temozolomide given with concurrent radiotherapy, followed by an additional maintenance phase of Temozolomide alone. The studied populations consisted of adults, often spanning different age groups, who had recently undergone surgery for their tumor. Researchers measured key endpoints such as Overall Survival (OS) (the length of time patients lived) and Progression-Free Survival (PFS) (the time until the tumor worsened or grew).

These large studies reported the observed measurements for Overall Survival and Progression-Free Survival endpoints, providing specific time-point data. Research also examined how certain molecular characteristics within the tumor cells, such as the status of the MGMT promoter, related to the patterns measured in the studies. These findings contribute to the broader evidence landscape used by regulators to understand the clinical evaluation of Temozolomide.

Evidence for Recurrent Malignant Glioma

The research base is different for recurrent malignant glioma, which includes tumors that was observed in patients whose tumors had returned or progressed after initial treatment. Research here primarily involves Phase II clinical trials and observational studies. These trials primarily used short-term endpoints, often measuring the Objective Response Rate and the Progression-Free Survival rate at six months (PFS-6). The patient groups included in this research were often heterogeneous (mixed tumor types and varying prior treatments), which means consistent conclusions are difficult to establish across the entire population. Comparative evidence is lacking from large, contemporary randomized trials against other modern salvage therapies.

What is Still Uncertain About the Research Base

Despite the existence of large Phase III trials for newly diagnosed GBM, certainty remains low in several key areas. The combined therapy was primarily compared to radiation alone, meaning the role of Temozolomide outside of this specific combination setting is not fully characterized. For recurrent disease, the evidence quality varies across studies due to reliance on non-randomized, single-arm trials. Therefore, the data are still emerging regarding the application of Temozolomide in patients whose tumor has progressed, and research is ongoing to address these evidence gaps.

Key Studies & References Temodar (Temozolomide) Capsules FDA Label and Approved Indications - DailyMed

Common questions about Темодал (FAQ)

Q: Can Темодал be used for any other cancers besides those of the brain?

A: Yes, official product information indicates that in addition to being indicated for newly diagnosed glioblastoma multiforme, it is also approved for treating anaplastic astrocytoma (another type of malignant glioma). The drug is used in adults and children three years of age and older when the tumor has returned or progressed following prior therapy.

Q: How does Темодал treatment fit into the overall plan for brain tumors?

A: For newly diagnosed glioblastoma, the treatment is typically structured into two main phases. It is first given in combination with radiotherapy (the concomitant phase) and is then followed by a period where the drug is administered on its own (the maintenance phase).

Q: How quickly do the side effects of Темодал typically start after beginning treatment?

A: The timing for side effects can vary. Common effects like nausea and vomiting may begin shortly after taking the drug. However, the most critical blood-related effects, known as myelosuppression (the lowest point of white blood cells and platelets), are typically observed around Day 22 of a standard 28-day cycle.

Q: What are the signs of a severe or serious side effect that need immediate attention?

A: Official labeling describes symptoms that require immediate reporting, which include signs of severe infection (such as a fever or chills) or signs of bleeding (like unusual bruising, black stools, or blood in urine). Signs of severe liver damage, such as yellowing of the skin or eyes, are also described in the documentation as requiring immediate reporting.

Q: What steps are outlined in official documents if a patient experiences nausea while on Темодал?

A: Official guidance refers to the use of anti-nausea medication prescribed by the physician and mentions the administration rule of taking the dose on an empty stomach to help with management. The official rule if a dose is vomited is to not take an extra or replacement dose.

Q: Are there certain over-the-counter medicines or supplements that should not be mixed with Темодал?

A: Regulatory guidance highlights the importance of informing the healthcare provider of all medicines being used, including prescription, over-the-counter (OTC) drugs, vitamins, and supplements. This is essential because interactions can occur that may potentially reduce the drug’s effectiveness or increase side effects.

Q: Is it safe to take pain relievers while on Темодал treatment?

A: Official guidance emphasizes that consulting with the treating physician or pharmacist is important before taking any pain reliever. The drug's potential effect on blood cell counts may alter the safety profile of some pain medications.

Q: Does Темодал have the potential to interact with herbal products like St. John's Wort?

A: Official guidance highlights the need for the healthcare team to be informed of all herbal products, teas, and supplements being used. The potential for non-traditional products to interact with chemotherapy is a possibility that may affect how the drug works.

Q: What does official guidance say about alcohol consumption while on Темодал?

A: Official patient guidance suggests that alcohol consumption during treatment should be discussed with the healthcare team. The concern noted is that alcohol may potentially worsen side effects or reduce the overall effectiveness of the treatment.

Q: Does being on Темодал treatment affect how certain blood thinners work?

A: The drug commonly causes a drop in platelets (blood cells necessary for clotting). The regulatory concern is the increased risk of bleeding due to this potential myelosuppression, making close monitoring of patients who are also taking blood thinners a standard procedure.

Q: Are there special restrictions on driving or operating machinery while taking Темодал?

A: Yes. Official patient guidance indicates that activities requiring alertness, such as driving or operating heavy machinery, should be avoided if side effects occur. Commonly reported effects that may impact these activities include fatigue, dizziness, or blurred vision.

Q: Does Темодал only treat the tumor, or does it also affect healthy cells?

A: The drug is a type of chemotherapy known as an alkylating agent that works by damaging the DNA of rapidly dividing cells to stop tumor growth. However, this mechanism also impacts rapidly dividing healthy cells throughout the body, which leads to common side effects like myelosuppression (low blood counts) and hair loss.

Q: Why is there a potential risk of bone marrow suppression with Темодал?

A: Bone marrow suppression (myelosuppression) is a risk that stems from the drug's fundamental mechanism of action. As a cytotoxic agent, it damages the DNA of cells that divide quickly, which includes the blood-producing cells in the bone marrow.

Q: Can Темодал impact the ability to heal from wounds or surgery?

A: Due to the drug's effects on rapidly dividing cells and the associated risk of low blood counts, official guidance emphasizes consulting with the healthcare team before undergoing any surgery or dental procedures. This consideration is noted because wounds may take longer to heal, and there is a potential for increased infection risk.

Q: What official warnings or boxed warnings are associated with Темодал?

A: Official labeling includes warnings for several serious risks. These include severe myelosuppression (critically low blood counts), hepatotoxicity (liver damage), and the potential risk of developing Myelodysplastic Syndrome (MDS) and other secondary cancers.

Q: Why is it important to have regular blood tests while taking Темодал?

A: Regular blood tests (including Complete Blood Count and Liver Function Tests) are necessary throughout treatment. This monitoring is done to identify serious risks like myelosuppression (low white blood cells and platelets) and hepatotoxicity (liver damage), which may lead to a required dose delay or change.

Q: Why do some people need to take a medication called 'PCP prophylaxis' with Темодал?

A: Patients who receive the drug concurrently with radiation therapy are known to have an increased risk of developing Pneumocystis Pneumonia (PCP), which is a serious infection. Preventative medication (prophylaxis) is often provided during this combined phase to mitigate that documented risk.

Q: Is there a link between taking Темодал and fertility issues later on?

A: Regulatory documents indicate a risk of irreversible infertility in male patients. Official guidance discusses the need for male patients to seek counseling regarding sperm cryopreservation before beginning treatment. The labels also stipulate that all patients with reproductive potential are required to use effective contraception.

Q: What is the evidence regarding the long-term safety of Темодал?

A: Official labeling explicitly notes that cases of Myelodysplastic Syndrome (MDS) and secondary malignancies (like a specific form of leukemia) have been observed in patients treated with this drug. These conditions represent the primary long-term safety concerns.

Q: How does TGA or FDA classify the safety of Темодал during pregnancy?

A: Official information notes that the drug has the potential to cause fetal harm. The Australian (AU) TGA formally classifies the drug as Pregnancy Category D, which indicates positive evidence of human fetal risk.

Q: Does Темодал affect how other chemotherapy drugs work?

A: Regulatory guidance highlights the necessity of informing the doctor of all drugs being taken, including other chemotherapy agents. This is because potential interactions with other myelosuppressive drugs can compound the risk of side effects, particularly bone marrow suppression.

Q: Is Темодал known to cause severe allergic reactions?

A: Yes, severe allergic reactions are possible. Official labeling lists hypersensitivity to the drug or to dacarbazine (a related compound) as a contraindication (a reason the drug must not be used), and allergic reactions are reported among the documented adverse events.

Q: Is it true that Темодал can cause an infection risk?

A: Yes. Due to its mechanism, the drug commonly causes a decrease in white blood cells (neutropenia), which compromises the immune system. This myelosuppression officially increases the risk of serious infections, including specific opportunistic infections like PCP.

Q: Can Темодал cause any changes to mood or mental clarity?

A: The official documentation lists a range of nervous system and psychiatric effects among the reported adverse reactions. These include symptoms such as confusion, anxiety, depression, amnesia (memory loss), and difficulty concentrating.

Q: Can Темодал affect the effectiveness of vaccines?

A: Yes. Due to its immunosuppressive effects, official patient guidance emphasizes that consultation with the healthcare team is necessary before receiving any vaccinations. The use of live vaccines is generally not recommended during treatment.

Q: Why is it important to keep Темодал away from light or moisture?

A: The drug must be handled carefully to preserve its quality. Official storage instructions state that the capsules must be stored in their original, tightly closed container and protected from moisture and light to maintain the drug’s stability and effectiveness.

The storage and disposal of temozolomide (Temodal) must strictly follow the conditions defined in official regulatory labeling.

Storage Conditions

Temozolomide capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, tightly closed, and stored away from excess heat and moisture. It must be kept out of the sight and out of the reach of children.

Handling and Disposal

The capsules must not be opened, chewed, or dissolved; they must be swallowed whole. If the capsule is damaged, contact with the powder must be avoided due to the drug’s cytotoxic classification, and any exposed area must be washed well with water right away.

Disposal of any unused or expired product requires consulting a healthcare professional and considering the official procedures for handling and disposing of anticancer drugs.